ABSTRACT OBJECTIVES This study sought to determine prognostic value of nonobstructive coronary artery disease (CAD) for atherosclerotic cardiovascular disease (ASCVD) events and to determine whether incorporation of this information into the pooled cohort equation reclassifies recommendations for statin therapy as defined by the 2013 guidelines for cholesterol management of the American College of Cardiology and American Heart Association (ACC/AHA).
In this study, we used published data on the prognostic value of nonobstructive CAD to determine whether incorporation of this information into the pooled cohort equation reclassifies recommendations for statin therapy as defined by the 2013 ACC/AHA guidelines for cholesterol management. To do so, we performed a meta-analysis, used the results to modify the ASCVD risk calculator, and applied it to a separate population to assess the reclassification.
METHODS SYSTEMATIC LITERATURE REVIEW AND DATA COLLECTION.
A meta-analysis was conducted in adherence to the MOOSE (Meta-analysis of Observational Studies in Epidemiology) guidelines for meta-analyses and systematic reviews of observational studies (9). Two physician scientists (H.E. and R.A.P.T) searched PubMed for eligible studies using pre-defined selection criteria ( Figure 1 ) and pre-defined search syntax for selection of studies that had assessed the prognostic value of coronary CTA published up to May 2016 (Online Appendix). No search restrictions were used, and references of included studies were manually checked to identify eligible studies missed by the primary search strategy. We included the eligible articles on the basis of the following criteria: study domain (patients with suspected CAD without a previous history of CAD); and index test (coronary CTA: obstructive CAD, nonobstructive CAD). If there was an overlap in study populations, the study with the largest population was included. We excluded animal studies, phantom studies, case reports (N < 10), and studies that did not report hazard ratios (HRs) for ASCVD events.
Abstracts and unpublished studies were not included, and no contact was made with publication authors. Emami et al.
CTA, Nonobstructive ASCVD Risk, and Statin Therapy We searched PubMed for eligible studies by using pre-defined selection criteria (see text and the Online Appendix) to select the studies that had assessed the prognostic value of coronary computed tomography angiography (CTA) published up to May 2016. We reviewed the abstracts and titles and subsequently the full texts of the selected articles and identified 2 studies that had a reported hazard ratio (HR) of nonobstructive coronary artery disease (CAD) for atherosclerotic cardiovascular disease (ASCVD) events.
Emami et al. Values are mean AE SD or n (%). *The status of included subjects in regards to their symptoms in the studies.
ASCVD ¼ atherosclerotic cardiovascular disease; CAD ¼ coronary artery disease; DLP ¼ dyslipidemia; DM ¼ diabetes mellitus; HTN ¼ hypertension.
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Reclassification of patients on the basis of the presence or absence of nonobstructive coronary artery disease (CAD) demonstrated that in patients without coronary artery disease, the highest original atherosclerotic cardiovascular disease (ASCVD) score that, in consideration of the prognostic value of the absence of coronary artery disease that would correspond to a revised score of 7.5%, ranged from 10.0% to 17.9% in African-American women and men and from 13.7% to 14.3% in Caucasian women and men, respectively. In patients with nonobstructive coronary artery disease, the lowest original atherosclerotic cardiovascular disease score that, in consideration of the prognostic value of the presence of nonobstructive coronary artery disease that would correspond to a revised score of 7.5%, ranged from 3.0%
to 5.9% in African-American women and men and from 4.4% to 4.6% in Caucasian women and men, respectively. CTA ¼ computed tomography angiography.
Emami et al. [4]) (1.0% vs. 1.1% 10-year ASCVD risk, respectively).
However, the caveat with the absence of CAC is that it does not necessarily exclude the presence of other ASCVDs such as stroke. HDL-C ¼ high-density lipoprotein cholesterol; SBP ¼ systolic blood pressure.
Emami et al.
